Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia

NCT06553638 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT06553638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06553638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Unknown status
Start date
August 12, 2024
Completion date
May 31, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasm